PROTHENA CORPORATION PUBLIC LIMITED COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $791.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-27
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $791.00K, a 43.66% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $1.40M, a 2.57% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $1.44M, a 178.19% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $518.00K, a 89.99% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $791.00K 10-K · filed 2026-02-27 | |
| 2024-12-31 | $1.40M 10-K · filed 2026-02-27 | $7.53M 10-K · filed 2025-02-27 |
| 2023-12-31 | $1.44M 10-K · filed 2026-02-27 | $615.00K 10-K · filed 2024-02-22 |
| 2022-12-31 | $518.00K 10-K · filed 2025-02-27 | |
| 2021-12-31 | $5.17M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $3.41M 10-K · filed 2023-02-28 | |
| 2019-12-31 | $4.52M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $2.21M 10-K · filed 2021-02-26 | |
| 2017-12-31 | -$8.24M 10-K · filed 2020-03-03 | |
| 2016-12-31 | $422.00K 10-K · filed 2019-03-15 | |
| 2015-12-31 | $214.00K 10-K · filed 2018-02-26 | |
| 2014-12-31 | $74.00K 10-K · filed 2017-02-27 | |
| 2013-12-31 | $164.00K 10-K · filed 2016-02-25 | |
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 | |
| 2011-12-31 | $205.00K 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |